Introduction
Fibrinogen is a 340 kDa plasma glycoprotein that plays an important role in blood clotting, cellular and matrix interactions, inflammation, wound healing, and neoplasia [1] .
Fibrinogen is consisting of a dimeric molecule of 3 polypeptide chains, Aα, Bβ and γ, which are mainly synthesized and assembled into a disulfide-linked hexameric molecule in hepatocytes and secreted into the bloodstream at a concentration of 1.8-3.5 g/L [2] . Aα-, Bβ-and γ-chains are composed of 610, 461 and 411 residues, which are encoded by FGA, FGB and FGG, respectively, that are clustered in a 50 kb region on the long arm of chromosome 4 (4q28-1; FGG, -2; FGA, -3; FGB) [3] . The three genes contain the following numbers of exons: six (included Aα-E isoform) for FGA, eight for FGB and ten for FGG.
Genetic mutations in fibrinogen chain genes have been associated with afibrinogenemia, hypofibrinogenemia and dysfibrinogenemia, as listed in the fibrinogen variant database (http://www.geht.org/databaseang/fibrinogen/), and the molecular bases for the genetic and/or post-translational changes that cause dysfibrinogenemia, hypofibrinogenemia and afibrinogenemia have been described [4, 5] . The prevalence of afibrinogenemia is lower than 1 in 1 million and that of hypofibrinogenemia is more frequent. However the prevalence of hypofibrinogenemia is difficult to establish because of the large number of asymptomatic cases. Mutations of afibrinogenemic patients have been reported about eighty cases, and they are identified in homozygosity or compound heterozygosity [5] .
Umbilical cord bleeding is manifested with 85% cases of afibrinogenemia in the neonatal period, whereas, bleeding with a later age-of-onset patient may occur in the skin, Fibrinogen Matsumoto IX: FGB and FGG gene splicing mutations 4 gastrointestinal tract, genitourinary tract, or the central nervous system. Furthermore first-trimester abortion is common in afibrinogenemic women, and paradoxically arterial and venous thromboembolic complications have been reported in afibrinogenemic patients.
Hypofibrinogenemic patients are usually asymptomatic, however first-trimester abortion occur in some women [5] .
Recently, we identified a novel hypofibrinogenemia associated with compound heterozygous mutations, which were the deletion of 4 nucleotides in FGB intron 6 (three T, one G, between FGB IVS6-10 and -16; TTTGTTT) and A>G substitution in FGG intron 3 (FGG IVS3-2 A/G), and designated the condition as Fibrinogen Matsumoto IX (M IX).
FGB IVS6∆4b was located near a 3'-intron-exon junction and FGG IVS3-2G involved replacement of the consensus splice acceptor site AG to GG [6, 7] . Both of the two mutations have not been reported and are identified for the first time.
Some cases of afibrinogenemia caused by aberrant mRNA have been reported to be associated with large deletions [8] [9] [10] or other genetic mutations that affect transcription [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] . We assumed that abnormal transcription of mRNA for FGB IVS6∆4b and/or FGG IVS3-2G caused hypofibrinogenemia. To determine whether the correct transcription of mRNAs from the M IX mutant genes occurred, we cloned the wild-type and mutant genes of FGB and FGG into expression vectors, transfected them into mammalian cells, and then analyzed the expressed mRNAs.
Materials and methods
This study was approved by the Ethical Review Board of Shinshu University School of Medicine. After informed consent had been obtained from the patient, blood samples were collected for the biochemical and genetic analyses.
Data of patient with Matsumoto IX
The patient was a 38-year-old man with type I diabetes mellitus and Hashimoto's disease. He and his family members showed no bleeding or thrombotic episodes, and coagulation test results were as follows: PT 11. 
DNA sequence analysis
Genomic DNA was extracted from whole blood cells using a DNA Extraction WB Kit (Wako Pure Chemical Ltd., Osaka, Japan), according to the manufacturer's instructions. To amplify all exons and exon-intron boundaries in the Aα-, Bβ-and γ-chain genes, 32 PCR primers were designed and the DNA was amplified by PCR as described elsewhere [25] .
The PCR products were purified from agarose gels and directly sequenced using a BigDye TM Terminator Cycle Sequencing Ready Reaction Kit and an ABI Prism 3100
Genetic Analyzer (both from Applied Biosystems, Foster City, CA, USA). To verify the deletion of the nucleotides or mutation detected by direct sequencing, the PCR products were subcloned into pCR2.1 plasmid vectors using an original TA Cloning Kit (Invitrogen, San Diego, CA, USA) under conditions recommended by the manufacturer, and the extracted subcloned plasmid vectors were sequenced as described above.
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Construction of expression vectors
DNA fragments spanning from intron 5 to the 3' untranslated region (UTR) in exon 8 of the Bβ-chain gene and from intron 2 to exon 5 of the γ-chain gene were amplified from the patient's genomic DNA using the primer couples FGB-IVS5-
). PCR-amplified fragments carrying the wild-type of the Bβ-and γ-chain genes were 1548 and 2396 bp, respectively. Purified PCR products of the Bβ-and γ-chain genes were inserted into pTARGET Vector and transfected into JM109 High Efficiency
Competent Cells using pTARGET TM Mammalian Expression Vector System (Promega, WI, USA), according to the manufacturer's instructions. Plasmid DNAs were isolated using a miniprep method and sequenced as described above. Four selected clones into which wildor mutant-type plasmid of the Bβ-or γ-chain gene had been inserted were cultured in a large amount of medium, and the plasmids were isolated using a Qiagen Plasmid Maxi Kit (Qiagen Sci, ML, USA). The base sequences of the plasmids were confirmed and named pT-Bβ-wild-type (wt), pT-Bβ-mutant-type (mt), pT-γ-wt and pT-γ-mt vectors.
Production of Bβ-and γ-chain mRNAs
The expression vectors pT-Bβ-wt, pT-Bβ-mt, pT-γ-wt and pT-γ-mt were introduced into Chinese hamster ovary (CHO) cells using lipofection. Briefly, 500 µL of antibiotic-free medium containing 8 µg of the vector DNA was mixed with an equal volume of 
RNA extraction and RT-PCR
The CHO cells were harvested 48 h after transfection. Total cellular RNA was extracted from cells using QIAamp RNA Blood Mini Kit (Qiagen), and contaminated DNA was cycles using the two pairs of primers that were used in the PCR of the fragment DNA Bβ-chain and γ-chain genes under the following conditions: denaturation at 93°C for 1 min, annealing at 51°C (Bβ-chain) or 56°C (γ-chain) for 1 min, and extension at 72°C for 1 min.
Analysis of the RT-PCR products by electrophoresis and sequencing
The amplified products were separated by electrophoresis on 2% agarose gels and purified from the gels using Gene Clean II Kit (Funakoshi, Tokyo, Japan). DNA fragments were sequenced as described above using the primers that were used for the PCR of the
Results

DNA sequence analysis of the Matsumoto IX patient
The Fig. 1-A, B) .
Analysis of fibrinogen Bβ-and γ-chain gene transcripts in CHO cells
To verify whether FGG IVS3-2G and/or FGB IVS6∆4b mutations influence transcription of mature mRNAs, mutant Bβ-and γ-chain mRNAs were transiently produced in CHO cells. We constructed 4 expression vectors, pT-Bβ-wt, pT-Bβ-mt, pT-γ-wt and pT-γ-mt, by cloning PCR-amplified genomic DNA fragments of the fibrinogen Bβ-and γ-chains, as described in Materials and methods.
The RT-PCR products from the CHO cells transfected with pT-Bβ-wt showed a major Fibrinogen Matsumoto IX: FGB and FGG gene splicing mutations 9 and a minor band, which were named Bβ-W1 and Bβ-W2, respectively, and those from cells transfected with pT-Bβ-mt showed a single band, named Bβ-M (Fig. 2-A) . The RT-PCR products from the CHO cells transfected with pT-γ-wt showed a single band that was named γ-W, and those with pT-γ-mt showed a major and a minor band, which were named γ-M1 and γ-M2, respectively (Fig. 2-B) . From the direct sequencing, Bβ-W1
showed a normal mRNA with correct splicing of exon 6 -exon 7 -exon 8; however, for Bβ-W2, exon 7-exon 8 were combined and followed exon 6 for which the initial 18 bases were deleted. For the mRNA of Bβ-M, exon 6 -intron 6 -exon 7 -intron 7 -exon 8 were combined, and so included not only intron 6 but also intron 7. The result indicated that the deletion of 4 nucleotides between IVS6-10 and -16 of the Bβ-chain led to incorrect transcription ( Fig. 2-A) .
Although the mRNA of γ-W was normal mRNA containing exon 3 -exon 4 -exon 5
( Fig. 2-B) , for γ-M1, exon 3 -intron 3 -exon 4 -exon 5 were combined, which constituted abnormal mRNA that included intron 3. For γ-M2, exon 3 -exon 4 -exon 5
were combined, and the product was generated using a cryptic 3' splice site 9-nt downstream from the beginning of exon 4.
Discussion
In this study, we described hypofibrinogenemia M IX associated with 2 novel mutations, one of which is the deletion of 4 nucleotides (three T, one G) situated in FGB IVS6-10 to -16 (TTTGTTT) (FGB IVS6∆4b), and the other is an A>G mutation situated at a splicing acceptor site at FGG IVS3-2. FGB IVS6∆4b is located a little downstream of FGB intron 6
Fibrinogen Matsumoto IX: FGB and FGG gene splicing mutations 10 than the acceptor splice site. On the other hand, the FGG IVS3-2A>G mutation converts the conserved dinucleotide AG acceptor splice site to GG [6, 7] .
To examine whether the cause of the low level of M IX plasma fibrinogen is FGG IVS3-2G and/or FGB IVS6∆4b, we analyzed the mRNAs transcribed from the cloned wild-type and mutant FGB and FGG genes in CHO cells; FGB including the region between intron 5 and exon 8 and FGG including that between intron 2 and intron 5. Our transient expression system using CHO cells indicated that both FGB IVS6∆4b and FGG IVS3-2G mutations induce complete inactivation of the normal 3' splice site. The alternative mRNA from FGB IVS6∆4b was an abnormal product that included both intron 6 and intron 7. In addition the FGG IVS3-2G gene generated two mRNA products. The major product (γ-M1) included intron 3 and the minor one (γ-M2) was an aberrant product using a cryptic 3' splice site in exon 4 and lacked 9 bp (ATATGATAGA) from the beginning of exon 4 (coding residues 134-136 of the γ-chain), which resulted in an aberrant γ-chain composed of 408 amino acids. Although two products were seen in the mRNA from Bβ-wt, it was assumed that the minor band (Bβ-W2) was a non-specific PCR product, because the sequence of the forward primer (GAA TGG ACA GGG GAT TCA GA) was similar to the beginning of exon 6 (GAT GGA CAG TGA TTC AGA). We considered that both Bβ-W2 and γ-M2 mRNAs might be produced by artificial transcription that occurred in the CHO cell expression system.
We predicted the amino-acid sequences that would be produced when the aberrant mRNAs of Bβ-M and γ-M1 are translated into proteins. The translational product of Bβ-M was predicted to have substituted aberrant amino acids from the 291st to the 307th residues Fibrinogen Matsumoto IX: FGB and FGG gene splicing mutations 11
and early termination at the 308th. Similarly, the translational product of γ-M1 was predicted to have substituted aberrant amino acids from the 77th to the 99th residues and early termination at the 100th. These aberrant proteins represented truncations of 154 residues from the Bβ-chain and 312 residues from the γ-chain. We could not observe the truncated Bβ-or γ-chain peptide in the patient's plasma by SDS-PAGE and immunoblot analyses using polyclonal fibrinogen antibody and monoclonal Bβ-or γ-chain antibodies under reducing conditions (data not shown); namely, neither truncated Bβ-nor γ-chain could interact with other chains to form a mature hexameric fibrinogen molecule. A previous report demonstrated that the premature termination codons in FGA are not associated with decay of the mutant mRNAs [26] . We speculated that the cause of the low level of M IX plasma fibrinogen was that the truncated Bβ and γ-chains are subjected to quality control and degraded by the ubiquitin-proteasome system [27, 28] , and/or the aberrant mRNAs are unstable and degraded before translation into proteins, such as via nonsense-mediated mRNA decay in the cytoplasm [29, 30] .
Reports on autosomal recessive disorder with a molecular base of congenital afibrinogenemia indicated association with the aberrant splicing caused by inactivation of physiologic splice sites [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] . Most abnormal RNA splicing was reported to occur near the donor splice site, with five kinds of mutation in FGA, four in FGB and three in the IVS3 +1 to +4 deletions, which were another FGA donor splice site mutation, showed exon 3 skipping in 99% of transcripts, and exon 2 and 3 skipping in 1% of transcripts [23] . On the other hand, mRNAs from FGB IVS6∆4b and FGG IVS3-2G, the mutations of both of which were located in acceptor splice sites, showed no splicing out of intron 6 and intron 7
in the Bβ-chain or of intron 3 in the γ-chain, respectively. We consider that the study of these splicing abnormalities reveals important information about mRNA splicing mechanisms.
Fibrinogen M IX is a novel hypofibrinogenemia with compound heterozygous mutation; however, we could not determine whether FGB IVS6∆4b and FGG IVS3-2G are present on the same allele or not, because consent for a test to determine this could not be obtained from the patient's family members.
Afibrinogenemias caused by splicing abnormalities have been reported with homozygous mutation, and there is a report that heterozygous splice site mutation of FGA does not cause hypofibrinogenemia [14] . We considered that the plasma fibrinogen level might be regulated by the expression level of Bβ-and/or γ-chain, and thus that the reduced plasma fibrinogen level of the M IX patient was caused by abnormal RNA splicing of one or both FGB and FGG genes. genes. (A) W1 was a normal mRNA, and W2 was an aberrant mRNA for which the initial 18 bases of exon 6 from the wild-type FGB gene were deleted. M was an aberrant mRNA from the FGB IVS6 gene for which 4 nucleotides had been deleted and included intron 6 and intron 7. (B) W was a normal mRNA from the wild-type FGG gene. M1 was an abnormal mRNA that included intron 3, and M2 showed that intron 3 was spliced by a cryptic splice site in exon 4 from the FGG IVS3+2G gene.
